₹ 14916 / 33 shares

IPO Details


Issue Date

06 May - 8 May'24


₹ 14916

Price Range

430 - 452

Lot Size


IPO Size

₹ 1842.65 Cr

IPO Listing Details

Listing On

13 May'24

Issue Price


Listed Price

₹ 655

Retail Gain/Listing Gain


Start date

End date

Allotment of bids

Refund Initiation

Listing on exchange

All you need to know about Indegene Limited IPO
Tune in to know more about the company, IPO issue details, product/service portfolio, and much more with Kinjal Parekh!

Founded in 1998, Indegene Limited provides digital services for the life sciences industry. They assist with drug development, clinical trials, regulatory submissions, pharmacovigilance, complaints management, and sales/marketing support.

The company's services can be divided into the following categories:

  1. Enterprise Commercial Solutions

  2. Omnichannel Activation

  3. Enterprise Medical Solutions

  4. Enterprise Clinical Solutions and consultancy services

Track record of establishing long-standing client relationships

Indegene has a solid track record of maintaining long-term relationships with major biopharmaceutical companies, including the top 20 largest biopharmaceutical companies by revenue for the Financial Year 2023. Indegene's high client stickiness is evidenced by its consistent retention rates: 122.83% in FY2023, 159.89% in FY2022, and 129.90% in FY2021. These enduring relationships and the deeply integrated nature of their solutions contribute to a significant proportion of recurring revenue.

Global delivery model

Indegene caters to clients from six operation hubs and 16 offices located across North America, Europe, and Asia. The company offers solutions through two primary delivery models: enterprise-wide technology-enabled Centers of Excellence (CoEs) and digital Omnichannel Activation solutions. The CoEs comprise subject matter experts who collaborate closely with clients to deliver multi-year, global solutions. The digital Omnichannel Activation capabilities allow Indegene to run sales and marketing campaigns digitally, reducing the need for biopharmaceutical companies to rely on traditional medical representatives. Indegene's global presence provides localised knowledge, allowing the company to work with clients across different regions, time zones, and languages.

Track record of creating value through acquisitions

Indegene has a successful track record of creating value through acquisitions, leveraging synergies, networks, technologies, and talent from acquired companies. Notable acquisitions include Encima Group, Inc. in 2016, which added capabilities in digital marketing and campaign operations, and a minority stake in DT Associates Research and Consulting Services Limited in 2019, later acquiring a majority stake in 2020. This acquisition enhanced Indegene's strategic consulting capabilities. The 2022 acquisition of Cult Health, a full-service healthcare marketing agency, further augmented Indegene's commercialisation portfolio with brand strategy, marketing development capabilities, and patient engagement platforms. These acquisitions have contributed to Indegene's expansion into new markets, access to new technologies, and a broader range of solutions for clients.
  • Indegene relies on sub-contractors and third-party service providers, who may not perform their obligations satisfactorily in compliance with the law, and Indegene may have no recourse against such sub-contractors and service providers.

  • Indegene's international operations are exposed to complex management, legal, tax, and economic risks, and exchange rate fluctuations, which could adversely affect business, financial condition, and results of operations.

  • Most of Indegene's revenue comes from its subsidiaries, so any disruptions in one or more of them could negatively impact the company's business, financial condition, and operational results.

Key Strategies

  • Strengthen the “go to market” engine

  • Develop technology portfolio

  • Pursue strategic acquisitions

Here are the key financials for Indegene Limited:

Particulars (in Rs. million)

Particulars (in Rs. million)

Applying for an IPO for the first time?
Here's a video playlist to help you invest in the upcoming Indegene Limited IPO
How to apply for IPO through ASBA

How to apply for IPO through ASBA

Kotak Securities

04m 01s

Opening of account will not guarantee allotment of shares in IPO. Investors are requested to do their own due diligence before investing in any IPO.

Here are the steps to apply for Indegene Ltd IPO:

Step 1: Log in to your Kotak Securities Demat account Log in to your Demat account to access IPO investments. Next, select the current IPO section.

Step 2: Specify IPO details Enter the number of lots and the price you wish to apply for.

Step 3: Enter UPI ID After entering your UPI ID, click submit. This will place your bid with the exchange.

Step 4: Mandate Notification Your UPI app will receive a mandate notification to block funds.

Step 5: Approve Request Your funds will be blocked once you approve the mandate request on your UPI.

Indegene IPO FAQs

Indegene IPO will list on 2024-05-13.

1842.65 is the issue size of Indegene IPO.

The minimum lot size is 33 shares and the investment required is ₹14916.

The price band of Indegene IPO is ₹430 to ₹452.

You can read more about Indegene and its IPO from the company’s red herring prospectus (RHP) here.

The Indegene Limited IPO has an issue size of Rs. 1,842 Cr. The IPO opens for subscription on 6th May 2024 and closes on 8th May 2024.

Link Intime India Private Limited is the registrar for this IPO.

Open Demat Account to Invest in any IPO
+91 -